Inclusion Criteria:  Men and women aged 18 and over Clinical status according to the WHO scale - 6, 7, 8 and 9 points. Verified respiratory infection COVID-19 by real-time PCR (quantitative)  Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:  women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year); men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility) Availability of signed and dated informed consent of the patient to participate in the study.  Exclusion Criteria:  Clinical status according to the WHO scale - 1, 2, 3, 4 and 5 points.  Increased risk of bleeding:  extensive bleeding at the present time; intracranial (including subarachnoid) hemorrhage at the present time. Lactation, pregnancy Known hypersensitivity to Fortelyzin®.